Abstract
Dendritic cell cancer vaccines have already become a treatment modality for patients with various cancer types. However, the curative potential of this immunotherapy is limited by the existence of negative feedback mechanisms that control dendritic cells (DCs) and T-cell function. By inhibiting the expression of inhibitory factors using RNA interference technology, a new generation of DC vaccines was developed. Vaccine-stimulated T cells showed antitumor effects both in vitro and in cancer patients. Here, we describe the development and validation of a fully GMP-compliant production process of ex vivo DC cancer vaccines combined with the blockade of immunosuppressive pathways using small interfering RNAs. The protocol can be used for DC-based therapy for all cancer types.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449:245–252
Hoos A, Britten CM, Huber C, O’Donnell-Tormey J (2011) A methodological framework to enhance the clinical success of cancer immunotherapy. Nat Biotechnol 29:867–870
Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS et al (2002) Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297:1867–1870
Hwu P, Du MX, Lapointe R, Do M, Taylor M-W, Young HA (2000) Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 164:3596–3599
Braun D, Longman RS, Albert ML (2005) A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic cell maturation. Blood 106:2375–2381
Munn DH, Sharma MD, Hou D (2004) Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in draining-draining lymph nodes. J Clin Invest 114:280–290
Jonuleit H, Schmitt E, Stenbrink K, Enk AH (2001) Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 22:394–400
Sioud M (2019) Releasing the immune system brakes using siRNAs enhances cancer immunotherapy. Cancers 11, cancers11020176
Sioud M (2011) Promises and challenges in developing RNAi as a research tool and therapy. Methods Mol Biol 703:173–187
Flatekval GF, Sioud M (2010) Modulation of dendritic cell function and maturation with mono- and bifunctional small interfering RNAs targeting indoleamine 2,3-dioxygenase. Immunology 128:e837–e848
Sioud M, Saebøe-Larssen S, Hetland TE, Kaern J, Mobergslien A, Kvalheim G (2013) Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients. Int J Oncol 43:280–288
Acknowledgments
This work was supported by the Norwegian Cancer Society.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Sæbøe-Larssen, S., Sioud, M. (2020). Improving Dendritic Cell Cancer Vaccine Potency Using RNA Interference. In: Sioud, M. (eds) RNA Interference and CRISPR Technologies. Methods in Molecular Biology, vol 2115. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0290-4_14
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0290-4_14
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0289-8
Online ISBN: 978-1-0716-0290-4
eBook Packages: Springer Protocols